Physician profile
Huy Le
NPI 1225490063
$2,454.00
in general payments reported to CMS, 2019-2025
21 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $817 · 2021: $525 · 2022: $406 · 2023: $58.67 · 2024: $214 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $544.05 | 2019-2025 | Breztri |
| Glaxosmithkline, LLC. | $482.32 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $341.40 | 2020-2025 | |
| Gilead Sciences, INC. | $289.87 | 2020-2024 | Vemlidy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.17 | 2019-2021 | |
| Abbvie INC. | $94.29 | 2019-2020 | |
| Biotronik INC. | $92.35 | 2020 | |
| Astellas Pharma US INC | $86.77 | 2020-2022 | |
| Amgen INC. | $60.15 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $46.41 | 2021 | |
| Genentech USA, INC. | $44.25 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.64 | 2020 | |
| Lilly USA, LLC | $38.69 | 2020-2023 | Jardiance |
| Amarin Pharma, INC. | $35.42 | 2019-2020 | |
| Evoke Pharma, INC. | $34.15 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $26.09 | 2022-2023 | Proclaim |
| Sunovion Pharmaceuticals INC. | $23.48 | 2022 | |
| Radius Health, INC. | $20.93 | 2020 | |
| Allergan, INC. | $20.03 | 2020 | |
| Sumitomo Pharma America, INC. | $17.32 | 2024 | Gemtesa |
| Pfizer INC. | $17.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huy Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.